Aethlon Medical Granted Full Ethics Approval for Hemopurifier® Cancer Trial

Aethlon Medical has received ethics approval from the Central Adelaide Local Health Network for a Hemopurifier® study in cancer patients with non-responsive solid tumors to anti-PD-1 antibody treatments like Keytruda® or Opdivo®. The study aims to assess safety, feasibility, and optimal dosing, valid until June 13, 2027.

The biotech industry continues to demonstrate resilience and innovation, with Aethlon Medical, Inc. (AEMD) taking a significant stride forward in the field of cancer treatment [1]. Aethlon, a medical therapeutic company focused on developing immunotherapeutic devices, announced that it has received ethics approval from the Central Adelaide Local Health Network (CALHN) for a Hemopurifier® study in cancer patients with non-responsive solid tumors to anti-PD-1 antibody treatments, such as Keytruda® or Opdivo® [1].

The trial, which aims to assess safety, feasibility, and optimal dosing, will be conducted in Australia and is valid until June 13, 2027 [1]. CALHN, located in Adelaide, is a prominent healthcare organization with a rich history of medical advancements, offering an ideal setting for this cutting-edge research [2].

Aethlon Medical's Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections by removing harmful exosomes from blood using its proprietary lectin-based technology [1]. This action has potential implications for cancer treatment, as exosomes may contribute to immune suppression and metastasis [1].

The Hemopurifier® holds two FDA breakthrough device designations and an open investigational device exemption (IDE) application related to the treatment of life-threatening viruses not addressed with approved therapies [1]. With a strong clinical pipeline and promising results, Aethlon Medical is well-positioned to make significant contributions to the advancement of cancer treatment.

In the meantime, Aethlon Medical is also making progress in the fight against COVID-19. The company recently announced the receipt of ethics board approval from the Maulana Azad Medical College (MAMC) in India for a second site in their ongoing clinical trial of the Hemopurifier® to treat severe COVID-19 cases in the ICU with severe or life-threatening disease [1].

References:

[1] Aethlon Medical Receives Ethics Board Approval to Add Second Site for Hemopurifier® Clinical Trial in Australia. (2023, May 22). Retrieved from https://www.aethlonmedical.com/news-media/press-releases/detail/459/aethlon-medical-receives-ethics-board-approval-to-add
[2] About Us. (n.d.). Retrieved from https://www.centraladelah.sa.gov.au/about-us